Patents by Inventor Toshio Doi
Toshio Doi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240103014Abstract: The present disclosure provides a method of detecting IgG4 and Smad1 in a biological sample from a subject with onset or a risk of onset of diabetic nephropathy.Type: ApplicationFiled: September 22, 2022Publication date: March 28, 2024Applicants: HuBit genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Go Ichien, Keiichi Yamamoto
-
Publication number: 20240032959Abstract: A wire feeding device includes a grip portion that grips and releases the wire and moves in the distal end direction and a proximal end direction; a push spring that biases the grip portion toward the distal end direction; and a slider and a hook that deform the push spring and increase a biasing force. When the deformation of the push spring by the slider and the hook is released, the wire gripped by the grip portion is fed to the distal end direction by the biasing force from the push spring, and the wire feeding device is configured to be operated in (i) a first mode in which the wire is continuously fed in the distal end direction according to a first predetermined operation and (ii) a second mode in which the wire is fed once in the distal end direction according to a second predetermined operation.Type: ApplicationFiled: October 13, 2023Publication date: February 1, 2024Applicant: ASAHI INTECC CO., LTD.Inventors: Toshio DOI, Yusaku FUJITA, Tomoki YAMAGIWA
-
Publication number: 20210285963Abstract: The present invention provides a test method which enables specific diagnosis of early-stage pathology of diabetic nephropathy. There is provided a method of detecting onset or a risk of onset of diabetic nephropathy, comprising measuring IgG4 in a biological sample derived from a subject. This method may further comprise measuring Smad1 in the biological sample derived from the subject. Preferably, both IgG4 and Smad1 are measured.Type: ApplicationFiled: September 26, 2017Publication date: September 16, 2021Applicants: HuBit genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Go Ichien, Keiichi Yamamoto
-
Patent number: 10828279Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.Type: GrantFiled: April 2, 2019Date of Patent: November 10, 2020Assignees: HUBIT GENOMIX, INC., FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Toshio Doi, Tatsuya Tominaga, Yui Fujita
-
Publication number: 20190314339Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.Type: ApplicationFiled: April 2, 2019Publication date: October 17, 2019Applicants: HuBit Genomix, Inc., Fuso Pharmaceutical Industries, Ltd.Inventors: Toshio Doi, Tatsuya Tominaga, Yui Fujita
-
Publication number: 20160333412Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: ApplicationFiled: May 4, 2016Publication date: November 17, 2016Applicants: HUBIT GENOMIX INC.Inventors: Toshio Doi, Hideharu ABE
-
Patent number: 9359645Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 28, 2009Date of Patent: June 7, 2016Assignees: HUBIT GENOMIX INC.Inventors: Toshio Doi, Hideharu Abe
-
Patent number: 8822911Abstract: Provided is a focused ion beam apparatus including a control portion configured to: store in advance, in a condenser voltage table, a calculation value of a condenser voltage for obtaining a reference beam current for all each of a plurality of apertures; obtain an experimental value of the condenser voltage for obtaining the reference beam current for a reference aperture; obtain a correction value of the condenser voltage by subtracting the calculation value stored for the reference aperture from the experimental value for the reference aperture; obtain setting values of the condenser voltage by adding the correction value to the calculation values stored for each of the plurality of the apertures; and store the obtained setting value in the condenser voltage table.Type: GrantFiled: March 15, 2013Date of Patent: September 2, 2014Assignee: Hitachi High-Tech Science CorporationInventors: Yasuhiko Sugiyama, Tatsuya Asahata, Toshio Doi, Hiroshi Oba
-
Patent number: 8774001Abstract: A relay device of relaying a communication packet is disclosed, which comprises: an input module configured to receive the communication packet as an input; a buffer configured to have a plurality of queues and temporarily accumulated the received communication packet; a sorter configured to sort the received communication packet to one of the plurality of queues, depending on a specific value obtained by a predetermined function that gives an aggregate output from an input which is transfer information regarding transfer of the communication packet; and a band controller configured to control a bandwidth for each of the plurality of queues and output communication packets accumulated in the plurality of queues for transmission of the communication packets. This ensures the quality of service, while saving the capacity of the buffer used for the queues.Type: GrantFiled: January 25, 2012Date of Patent: July 8, 2014Assignee: Alaxala Networks CorporationInventors: Takeshi Kumagai, Nobuhito Matsuyama, Takeshi Aimoto, Toshio Doi, Kazuo Sugai
-
Publication number: 20130240720Abstract: Provided is a focused ion beam apparatus including a control portion configured to: store in advance, in a condenser voltage table, a calculation value of a condenser voltage for obtaining a reference beam current for all each of a plurality of apertures; obtain an experimental value of the condenser voltage for obtaining the reference beam current for a reference aperture; obtain a correction value of the condenser voltage by subtracting the calculation value stored for the reference aperture from the experimental value for the reference aperture; obtain setting values of the condenser voltage by adding the correction value to the calculation values stored for each of the plurality of the apertures; and store the obtained setting value in the condenser voltage table.Type: ApplicationFiled: March 15, 2013Publication date: September 19, 2013Applicant: HITACHI HIGH-TECH SCIENCE CORPORATIONInventors: Yasuhiko SUGIYAMA, Tatsuya ASAHATA, Toshio DOI, Hiroshi OBA
-
Publication number: 20120188874Abstract: A relay device of relaying a communication packet is disclosed, which comprises: an input module configured to receive the communication packet as an input; a buffer configured to have a plurality of queues and temporarily accumulated the received communication packet; a sorter configured to sort the received communication packet to one of the plurality of queues, depending on a specific value obtained by a predetermined function that gives an aggregate output from an input which is transfer information regarding transfer of the communication packet; and a band controller configured to control a bandwidth for each of the plurality of queues and output communication packets accumulated in the plurality of queues for transmission of the communication packets. This ensures the quality of service, while saving the capacity of the buffer used for the queues.Type: ApplicationFiled: January 25, 2012Publication date: July 26, 2012Inventors: TAKESHI KUMAGAI, Nobuhito Matsuyama, Takeshi Aimoto, Toshio Doi, Kazuo Sugai
-
Patent number: 8025881Abstract: When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.Type: GrantFiled: July 19, 2007Date of Patent: September 27, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe, Naoshi Fukushima, Hitoshi Tai, Takakazu Mizuno, Masahiko Kinosaki
-
Patent number: 7901874Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: March 8, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Patent number: 7862993Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: GrantFiled: September 9, 2004Date of Patent: January 4, 2011Assignees: Hubit Genomix, Inc., Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe
-
Patent number: 7839878Abstract: A network connection apparatus including: a plurality of line connection parts connected to network lines to transmit and receive packets; a transmission destination decision part for deciding a transmission destination on the basis of header information of a packet received by a first one of the plurality of line connection parts; a packet transfer part for transferring packets to a second line connection destination corresponding to the transmission destination decided by the transmission destination decision part; and, a power supply part for supplying power to the line connection parts and a power control part for controlling supply of power to each of the line connection parts from the power supply part.Type: GrantFiled: July 18, 2006Date of Patent: November 23, 2010Assignee: Alaxala Networks CorporationInventors: Shunsuke Hino, Toshio Doi, Motoyuki Unno
-
Patent number: 7764599Abstract: A network routing device according to the invention transmits a packet via a second port based upon destination information included in the packet received via a first port referring to a routing table. In addition, the network routing device calculates beforehand a third port which is a transfer destination when a fault occurs in a destination connected to the second port. Further, the network routing device holds scenario information including a combination of the second port and the third port and updates the routing table based upon the scenario information when a fault is detected in either of the ports.Type: GrantFiled: February 7, 2007Date of Patent: July 27, 2010Assignee: ALAXALA Networks CorporationInventors: Toshio Doi, Yukimasa Komahara
-
Publication number: 20100135988Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: ApplicationFiled: September 28, 2009Publication date: June 3, 2010Inventors: Toshio Doi, Hideharu Abe
-
Publication number: 20100003245Abstract: When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.Type: ApplicationFiled: July 19, 2007Publication date: January 7, 2010Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Toshio Doi, Hideharu Abe, Naoshi Fukushima, Hitoshi Tai, Takakazu Mizuno, Masahiko Kinosaki
-
Method of correcting opaque defect of photomask using atomic force microscope fine processing device
Patent number: 7571639Abstract: An opaque defect is processed by scanning with a high load or height fixed mode using a probe harder than a pattern material of a photomask at the time of going scanning, and is observed by scanning with a low load or intermittent contact mode at the time of returning scanning so as to detect an ending point of the opaque defect by the height information. When there is a portion reaching to a glass substrate as an ending point, this portion is not scanned by the high load or height fixed mode in the next processing, and only a portion not reaching to the ending point is scanned by the high load or height fixed mode.Type: GrantFiled: April 27, 2007Date of Patent: August 11, 2009Assignee: SII NanoTechnology Inc.Inventors: Toshio Doi, Kazutoshi Watanabe, Osamu Takaoka, Atsushi Uemoto -
Publication number: 20080025967Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.Type: ApplicationFiled: September 9, 2004Publication date: January 31, 2008Inventors: Toshio Doi, Hideharu Abe